APP and early-onset autosomal dominant Alzheimer disease: During the last few years, various selective APP γ-secretase inhibitors have been developed (Basi et al., 2010, Fleisher et al., 2008, Probst et al., 2013) as strategic tools to reduce Aβ levels in Alzheimer's disease.